Sona Nanotech Updates on Timing of Clinical In-Field Validation Studies for its COVID-19 Antigen Test
Sona Nanotech announces that its previously announced clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test that commenced...
BioHarvest Sciences Inc. Announces Manufacturing Agreement with Sugart Ltd. and Details of Its Growth Strategy
BioHarvest Sciences Inc. (CSE: BHSC) (the “Company”, “BioHarvest”) announces today its growth strategy supported by a major manufacturing agreement allowing...
Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Algernon Pharmaceuticals Inc. has enrolled its first patient in its multinational Phase 2b3 human study of NP-120 for the treatment...
Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics is pleased to announce that following the U.S. Food & Drug Administration approval to proceed with the Company’s...
Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that the first patient has been dosed in...
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics announces that the U.S. Food & Drug Administration has approved the Company to proceed with a randomized, double-blind,...
Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial
Naturally Splendid Enterprises Ltd. is pleased to announce that the Company's phase 2 clinical trial, as per its proposed joint...